SCHEMBL259629 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	RAB9A	P51151	9/20	0.59

▸	GAA	P10253	5/20	0.51

▸	KMT2A	Q03164	7/20	0.51

▸	NPC1	O15118	6/20	0.51

▸	HPGD	P15428	1/20	0.51

▸	KDM4E	B2RXH2	8/20	0.46

▸	MAPT	P10636	8/20	0.46

▸	MEN1	O00255	4/20	0.46

▸	ALDH1A1	P00352	3/20	0.46

▸	GFER	P55789	2/20	0.46

▸	AHR	P35869	1/20	0.46

▸	SMN1; SMN2	Q16637	1/20	0.46

▸	CA12	O43570	1/20	0.45

▸	CA1	P00915	1/20	0.45

▸	CA2	P00918	1/20	0.45

▸	CA9	Q16790	1/20	0.45

▸	RECQL	P46063	1/20	0.45

▸	RXFP1	Q9HBX9	1/20	0.45

▸	NPSR1	Q6W5P4	2/20	0.44

▸	MAPK1	P28482	2/20	0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL3159586	0.76	RAB9A (0.59)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL9880650	0.76	ERCC1 (0.49)	RAB9AGAANPC1KDM4EMAPT
SCHEMBL4799793	0.76	RAB9A (0.59)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL3159327	0.76	KMT2A (0.55)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL4737060	0.74	RAB9A (1.00)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL4735233	0.73	KMT2A (0.57)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL3169921	0.72	RAB9A (0.50)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL4741277	0.72	GAA (0.68)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL10898618	0.72	RAB9A (0.54)	RAB9AGAAKMT2ANPC1HPGD
SCHEMBL4735887	0.72	RAB9A (0.93)	RAB9AGAAKMT2ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9592230-B2	Substituted imidazoles as PDE10A inhibitors	H. LUNDBECK A/S (DK)	2017-03-14	—	—	US	disclosed
US-9592230-B2	Substituted imidazoles as PDE10A inhibitors	H. LUNDBECK A/S (DK)	2017-03-14	—	—	US	disclosed
US-9592230-B2	Substituted imidazoles as PDE10A inhibitors	H. LUNDBECK A/S (DK)	2017-03-14	—	—	US	disclosed
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	H. LUNDBECK A/S (DK)	2015-07-09	—	—	US	disclosed
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	H. LUNDBECK A/S (DK)	2015-07-09	—	—	US	disclosed
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	H. LUNDBECK A/S (DK)	2015-07-09	—	—	US	disclosed
US-9018217-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-04-28	—	—	US	disclosed
US-9018217-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-04-28	—	—	US	disclosed
US-9018217-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-04-28	—	—	US	disclosed
US-20150025081-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2015-01-22	—	—	US	disclosed
US-8133897-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2012-03-13	—	—	US	disclosed
WO-2012007006-A1	TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR	H. LUNDBECK A/S (DK)	2012-01-19	—	—	WO	disclosed
WO-2012007006-A1	TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR	H. LUNDBECK A/S (DK)	2012-01-19	—	—	WO	disclosed
EP-2318394-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. Lundbeck A/S (DK)	2011-05-11	—	—	EP	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
WO-2009152825-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2009-12-23	—	—	WO	disclosed
WO-2009152825-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2009-12-23	—	—	WO	disclosed
WO-2008085008-A1	T-CELL INHIBITING COMPOUNDS AND THEIR USE FOR THE TREATMENT OF T-CELL-MEDIATED DISEASES	MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE (KR)	2008-07-17	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	PDE10A, PDE5A, PDE3B	RAB9A 722/4885GAA 32/4885KMT2A 1113/4885
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	PDE10A, PDE5A, PDE3B	RAB9A 722/4885GAA 32/4885KMT2A 1113/4885
US-20150025081-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	PDE10A, PDE5A, PDE3B	RAB9A 722/4885GAA 32/4885KMT2A 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.